{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:03:09Z","timestamp":1792519389046,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The pathogenesis of autoimmune hemolytic anemia (AIHA) remains incompletely understood, typically associated with immune dysfunction and the production of autoantibodies. Zuberitamab, a novel anti-CD20 monoclonal antibody, represents an important therapeutic strategy for managing autoimmune diseases. Here, we present the first case of a patient diagnosed with AIHA who developed severe immunosuppression, lymphopenia, and B-cell depletion following zuberitamab treatment, ultimately resulting in severe <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia(PJP). This case highlights the complexities of B-cell-targeted immunotherapy and underscores the necessity of close monitoring of immune status in patients receiving zuberitamab or other targeted immunotherapies to mitigate the risk of severe immune-related adverse events.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1546571","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:08:37Z","timestamp":1741676917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Severe Pneumocystis jirovecii pneumonia following zuberitamab treatment in autoimmune hemolytic anemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Qian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat Rev Dis Prime"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3760\/cma.j.issn.0253-2727.2023.01.003","article-title":"Chinese guideline for the diagnosis and treatment of adult autoimmune hemolytic anemia (2023)","volume":"44","year":"2023","journal-title":"Chin J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2023","journal-title":"Eur J Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights [published correction appears in Nat Rev Drug Discov. 2024 Nov 26. doi: 10.1038\/s41573-024-01103-2","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788830","article-title":"Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders","volume":"12","author":"Kaegi","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"MAbs"},{"key":"B9","article-title":"National Medical Products Administration","year":""},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101096","article-title":"Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"47","author":"Xu","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"B14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000487713","article-title":"Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jirovecii pneumonia","volume":"96","author":"Salzer","year":"2018","journal-title":"Respiration"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0360ED","article-title":"An emerging role of B cell immunity in susceptibility to pneumocystis pneumonia","volume":"56","author":"Kolls","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.10.6147","article-title":"B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection","volume":"176","author":"Lund","year":"2006","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.3.1423","article-title":"Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody","volume":"171","author":"Lund","year":"2003","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500112","article-title":"B lymphocytes are required during the early priming of CD4+ T cells for clearance of pneumocystis infection in mice","volume":"195","author":"Opata","year":"2015","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00744-13","article-title":"B cell production of tumor necrosis factor in response to Pneumocystis murina infection in mice","volume":"81","author":"Opata","year":"2013","journal-title":"Infect Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae133","article-title":"CD40 expression by B cells is required for optimal immunity to murine pneumocystis infection","volume":"230","author":"Sassi","year":"2024","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18862","article-title":"Prophylaxis against pneumocystis pneumonia","volume":"330","author":"Caplan","year":"2023","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07489-2","article-title":"Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study","volume":"50","author":"Kamel","year":"2024","journal-title":"Intensive Care Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.007","article-title":"Primary prophylaxis for pneumocystis jirovecii pneumonia in patients receiving rituximab","volume":"161","author":"Park","year":"2022","journal-title":"Chest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07547-9","article-title":"Severe Pneumocystis jirovecii pneumonia: time to reassess our practices","volume":"50","author":"Nseir","year":"2024","journal-title":"Intensive Care Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.05.558","article-title":"Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases","volume":"158","author":"Ghembaza","year":"2020","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults [published correction appears in JAMA. 2023 Oct 3;330(13):1289. doi: 10.1001\/jama.2023.19021","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1546571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:08:41Z","timestamp":1741676921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1546571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1546571"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1546571","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1546571"}}